In this grand rounds, we focus on development, validation, and application of neuroimaging biomarkers for Parkinson disease (PD). We cover whether such biomarkers can be used to identify presymptomatic individuals (probably yes), provide a measure of PD severity (in a limited fashion, but frequently done poorly), investigate pathophysiology of parkinsonian disorders (yes, if done carefully), play a role in differential diagnosis of parkinsonism (not well), and investigate pathology underlying cognitive impairment (yes, in conjunction with postmortem data). Along the way, we clarify several issues about definitions of biomarkers and surrogate endpoints. The goal of this lecture is to provide a basis for interpreting current literature and newly proposed clinical tools in PD. In the end, one should be able to critically distinguish fact from fantasy.

Original languageEnglish
Pages (from-to)769-783
Number of pages15
JournalAnnals of neurology
Issue number6
StatePublished - Dec 1 2014


Dive into the research topics of 'Neuroimaging biomarkers for Parkinson disease: Facts and fantasy'. Together they form a unique fingerprint.

Cite this